The overproduction of immunoglobulin E (IgE) resulting from alterations in the humoral immune response contributes to the development of allergic and atopic diseases such as allergic asthma and rhinitis, chronic spontaneous urticaria or food allergies and acute anaphylaxis.
Seismic Therapeutic Inc. has provided preclinical data for S-4321, a novel dual-cell bidirectional (DcB) PD-1:FcγRIIb antibody being developed for the treatment of autoimmune disease.
Seismic Therapeutic Inc.'s S-1117 was designed as a pan-IgG protease fused to an effector function silent human IgG1 Fc domain. The candidate, being developed for the treatment of autoantibody-mediated diseases, was engineered for chronic subcutaneous administration using a proprietary machine learning-enabled platform, with the aim of reducing immunogenicity while maintaining potency.
Myasthenia gravis (MG) is an antibody-mediated chronic neuromuscular disorder leading to fluctuating weakness and early muscle fatigue, with limited treatment options available. In MG, such as other autoimmune diseases, the main pathogenic autoantibody involved is the immunoglobulin G (IgG) isotype.
Autoantibodies can promote inflammation and activate complement pathways and immune cell responses causing tissue damage in autoantibody-driven diseases. Researchers from Seismic Therapeutic Inc. have presented data on S-1117.
The generation of pathogenic autoantibodies is a crucial event in the development of inflammation and complement activation, leading to immune cell responses.
Seismic Therapeutic Inc. has closed a $121 million series B financing to support progression of the company’s two lead programs through clinical proof of mechanism.
These days it’s nearly impossible to turn around in the biopharma world without hearing about how some company is going to use machine learning to revolutionize drug development. “It really is a catchphrase,” acknowledged Jo Viney, whose latest startup, Seismic Therapeutic Inc. launched with a $101 million series A round to advance a platform incorporating machine learning capabilities to find new drugs for autoimmune diseases.
